Evidence map›Paper›PMID 41993359›Full record

ArticlebioRxiv : the preprint server for biology2026

KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.

Saikat Chowdhury, Ichiaki Ito, Vinay K Pattalachinti, Abdelrahman Mg Yousef, Mahmoud Mg Yousef, Sacha El Khoury, Nicholas Hornstein, Ashlee Nichole Seldomridge, David Hong, Micheal J Overman and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Saikat ChowdhuryDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ichiaki ItoDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vinay K PattalachintiDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abdelrahman Mg YousefDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mahmoud Mg YousefDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sacha El KhouryDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nicholas HornsteinNorthwell Cancer Institute, New York, NY, USA.
Ashlee Nichole SeldomridgeDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David HongDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Micheal J OvermanDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Melissa W TaggartDepartment of Pathology, Division of Pathology-Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wai Chin FooDepartment of Pathology, Division of Pathology-Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Beth HelminkDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Keith F FournierDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
John Paul ShenDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Background: Appendiceal adenocarcinoma (AA) is a rare cancer with limited treatment options. Methods: We evaluated KRAS Results: MRTX1133 was highly effective for KRAS Conclusions: While effective suppression of RAS/ERK signaling by KRAS inhibitors reduces tumor growth, adaptive activation of EMT and TGF-β pathways may mediate resistance in

Identifiers

PMID41993359
PMCPMC13082064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.